Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 37,700 shares, a decline of 82.9% from the June 30th total of 220,500 shares. Based on an average trading volume of 352,900 shares, the short-interest ratio is presently 0.1 days. Approximately 7.8% of the shares of the stock are short sold.
Institutional Investors Weigh In On Bluejay Diagnostics
An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned 1.95% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.47% of the company’s stock.
Bluejay Diagnostics Stock Down 9.3 %
BJDX traded down $0.06 during trading on Friday, hitting $0.58. The company’s stock had a trading volume of 391,460 shares, compared to its average volume of 646,816. Bluejay Diagnostics has a 12 month low of $0.51 and a 12 month high of $89.12. The stock has a market capitalization of $325,640.00, a price-to-earnings ratio of -0.01 and a beta of 0.82. The firm’s 50 day moving average price is $2.38 and its two-hundred day moving average price is $4.72.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- 5 Top Rated Dividend Stocks to Consider
- Why Call Options Volume for These 2 Stocks Spiked Together
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 7/22 – 7/26
- How to Choose Top Rated Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.